Bite-X

Informazioni principali

  • Nome commerciale:
  • Bite-X flüssig
  • Forma farmaceutica:
  • flüssig
  • Composizione:
  • sacchari octaacetas 159 mg, acetonum, ethanolum, ethylcellulosum, povidonum, toluenum, antiox.: E 320, ad solutionem pro 1 ml.
  • Utilizzare per:
  • Esseri umani
  • Tipo di medicina:
  • Farmaco biologico

Documenti

  • per i professionisti:
  • Il foglio illustrativo per questo prodotto non è al momento disponibile, é possibile inviare una richiesta al nostro Servizio Clienti ed essere avvisati nel momento in cui è disponibile sulla nostra piattaforma.


    Richiedi il foglio illustrativo per i professionisti.

Localizzazione

  • Disponibile in:
  • Bite-X flüssig
    Svizzera
  • Lingua:
  • italiano

Informazioni terapeutiche

  • Gruppo terapeutico:
  • Synthetika
  • Area terapeutica:
  • Gegen Nagelbeissen

Altre informazioni

Status

  • Fonte:
  • Swissmedic - Swiss Agency for Therapeutic Products
  • Numero dell'autorizzazione:
  • 30945
  • Data dell'autorizzazione:
  • 17-02-1965
  • Ultimo aggiornamento:
  • 19-10-2018

Foglio illustrativo: composizione, posologia, indicazioni, interazioni, gravidanza, allattamento, effetti indesiderati, controindicazioni

Patienteninformation

Bite-X

DOETSCH GRETHER

Che cos'è Bite-X e quando si usa?

Bite-X è usato come rimedio contro il vizio di rosicchiare le unghie e succhiare il pollice. Le dita

trattate con Bite-X hanno un sapore amaro, così da scoraggiare la cattiva abitudine di mettere in

bocca e succhiare il pollice e le altre dita o di rosicchiare le unghie.

Quando non si può usare Bite-X?

Bite-X non può essere usato per i neonati (sotto 1 anno), dato che spesso non trovano sgradevole il

suo sapore amaro.

Quando è richiesta prudenza nell'uso di Bite-X?

Se usato correttamente non è necessario adottare particolari precauzioni.

Informi il suo medico, il suo farmacista o droghiere nel caso in cui soffre di altre malattie, soffre di

allergie o assume o applica altri medicamenti (anche se acquistati di sua iniziativa).

Si può usare Bite-X durante la gravidanza o l'allattamento?

In base alle esperienze fatte finora, non sono noti rischi per il bambino, se il medicamento è usato

correttamente. Tuttavia non sono mai stati effettuati studi scientifici sistematici. Per precauzione

dovrebbe rinunciare nella misura del possibile ad assumere medicamenti durante la gravidanza e

l‘allattamento o chiedere consiglio al suo medico o al suo farmacista.

Come usare Bite-X?

Per adulti e bambini a partire da 1 anno:

Applicare sull’unghio e intorno ad esso uno strato sottile di Bite-X. Lasciare asciugare un momento.

Si consiglia di ripetere l’applicazione dopo alcune ore – soprattutto alla sera prima di coricarsi – e

continuare per alcuni giorni, finché non viene abbandonata l‘abitudine di rosicchiare le unghie e di

succhiare il pollice. Chiudere bene il flaconcino dopo l’uso.

Si attenga alla posologia indicata nel foglietto illustrativo o prescritta dal medico. Se ritiene che

l’azione medicamento sia troppo debole o troppo forte ne parli al suo medico, al suo farmacista o al

suo droghiere.

Quali effetti collaterali può avere Bite-X?

Finora non sono stati osservati effetti collaterali in seguito all'uso corretto di Bite-X.

Se osserva ciononostante effetti collaterali qui non descritti, dovrebbe informare il suo medico, il suo

farmacista o il suo droghiere.

Di che altro occorre tener conto?

Bite-X è destinato solo all’uso esterno. Il preparato non deve entrare in contatto con gli occhi.

Il medicamento non dev’essere utilizzato oltre la data indicata con «EXP» sulla confezione.

Conservare a temperatura ambiente (15-25 °C).

Tenere fuori dalla portata dei bambini.

Cosa contiene Bite-X?

1 ml di Bite-X contiene:

Principo attivo: 159 mg di saccarosio-octaacetato.

Sostanze ausiliarie: acetone, etanolo, etilcellulosa, povidone, toluolo.

Antiossidante: butilidrossionisolo (E320).

Numero dell'omologazione

30945 (Swissmedic).

Dov'è ottenibile Bite-X? Quali confezioni sono disponibili?

In farmacia e in drogheria senza prescrizione medica.

Flaconcino da 15 ml.

Titolare dell’omologazione

Doetsch Grether SA, 4051 Basilea.

Questo foglietto illustrativo è stato controllato l’ultima volta nel novembre 2003 dall’autorità

competente in materia di medicamenti (Swissmedic).

17-1-2019

Safety of cassia gum as a feed additive for cats and dogs based on a dossier submitted by Glycomer GmbH

Safety of cassia gum as a feed additive for cats and dogs based on a dossier submitted by Glycomer GmbH

Published on: Wed, 16 Jan 2019 The additive cassia gum consists mainly of high-molecular weight polysaccharides composed primarily of a linear chain of 1,4-b-D-mannopyranose units with 1,6-linked a-D-galactopyranose units. In 2014, the Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) delivered an opinion on the safety and efficacy of cassia gum in cats and dogs. The Panel concluded, based on positive findings observed in a bacterial reverse mutation test with a semi-refined cassia...

Europe - EFSA - European Food Safety Authority EFSA Journal

13-12-2018

Pest categorisation of Septoria malagutii

Pest categorisation of Septoria malagutii

Published on: Wed, 12 Dec 2018 The Panel on Plant Health performed a pest categorisation of Septoria malagutii, the causal agent of annular leaf spot of potato, for the EU. The pest is a well‐defined fungal species and reliable methods exist for its detection and identification. S. malagutii is present in Bolivia, Ecuador, Peru and Venezuela. The pest is not known to occur in the EU and is listed as Septoria lycopersici var. malagutii in Annex IAI of Directive 2000/29/EC, meaning its introduction into t...

Europe - EFSA - European Food Safety Authority Publications

29-11-2018

Glyphosate: ANSES launches a comparative assessment with the available alternatives

Glyphosate: ANSES launches a comparative assessment with the available alternatives

Following the five-year re-approval of this active substance at European level in December 2017, ANSES is reassessing marketing authorisations for products containing glyphosate. For products for which an application for authorisation or re-authorisation has been submitted, the Agency will carry out a comparative assessment with the available alternatives. For each glyphosate-based product, all uses for which there is an alternative that meets the substitution criteria will therefore be prohibited.

France - Agence Nationale du Médicament Vétérinaire

17-10-2018

Pest categorisation of Stagonosporopsis andigena

Pest categorisation of Stagonosporopsis andigena

Published on: Tue, 16 Oct 2018 00:00:00 +0200 The Panel on Plant Health performed a pest categorisation of Stagonosporopsis andigena, the causal agent of black blight of potato, for the EU. The pest is a well‐defined fungal species and reliable methods exist for its detection and identification. S. andigena is present in Bolivia and Peru. The pest is not known to occur in the EU and is listed in Annex IAI of Directive 2000/29/EC as Phoma andina, meaning its introduction into the EU is prohibited. The ma...

Europe - EFSA - European Food Safety Authority Publications

17-10-2018

Pest categorisation of Thecaphora solani

Pest categorisation of Thecaphora solani

Published on: Tue, 16 Oct 2018 00:00:00 +0200 The Panel on Plant Health performed a pest categorisation of the fungus Thecaphora solani, the causal agent of smut of potato, for the EU. The identity of the pest is well established and reliable methods exist for its detection and identification. T. solaniis present in Bolivia, Chile, Colombia, Ecuador, Mexico, Panama, Peru and Venezuela. The pathogen is not known to occur in the EU and is listed in Annex IAI of Directive 2000/29/EC, meaning its introducti...

Europe - EFSA - European Food Safety Authority Publications

7-9-2018

Orphan designation:  Recombinant human beta-glucuronidase (vestronidase alfa),  for the: Treatment of mucopolysaccharidosis type VII (Sly syndrome)

Orphan designation: Recombinant human beta-glucuronidase (vestronidase alfa), for the: Treatment of mucopolysaccharidosis type VII (Sly syndrome)

On 21 March 2012, orphan designation (EU/3/12/973) was granted by the European Commission to NDA Regulatory Science Ltd, United Kingdom, for recombinant human beta-glucuronidase for the treatment of mucopolysaccharidosis type VII (Sly syndrome).

Europe - EMA - European Medicines Agency

7-9-2018

Jacent recalls Crave Party Candles

Jacent recalls Crave Party Candles

Candles which can spontaneously re-ignite are prohibited in Canada by the Candles Regulations under the Canada Consumer Product Safety Act as they can re-ignite after disposal, potentially causing fires.

Health Canada

29-8-2018

Protocol for the scientific opinion on the Tolerable Upper Intake Level of dietary sugars

Protocol for the scientific opinion on the Tolerable Upper Intake Level of dietary sugars

Published on: Fri, 10 Aug 2018 00:00:00 +0200 In June 2016, EFSA received a mandate from the national food competent authorities of five European countries (Denmark, Finland, Iceland, Norway and Sweden) to provide a dietary reference value (DRV) for sugars, with particular attention to added sugars. A draft protocol was developed with the aim of defining as much as possible beforehand the strategy that will be applied for collecting data, appraising the relevant evidence, and analysing and integrating t...

Europe - EFSA - European Food Safety Authority Publications

2-6-2018

Sanders Issues Allergy Alert on Undeclared Almonds in Fudge Mini Bites

Sanders Issues Allergy Alert on Undeclared Almonds in Fudge Mini Bites

Sanders announced today that it is recalling its 3.75oz Milk Chocolate Covered Fudge Mini Bites because they may contain undeclared almonds. People who have allergies to almonds run the risk of serious or life-threatening allergic reaction if they consume these products.

FDA - U.S. Food and Drug Administration

25-5-2018

Safe use of personal insect repellents

Safe use of personal insect repellents

While enjoying the warm summer weather, don't forget to protect yourself from pesky bugs that bite! Health Canada is reminding Canadians to use bug spray and other insect repellents safely to avoid mosquito and other bug bites.

Health Canada

21-5-2018

Melanie Wholesale Issues Allergy Alert on Undeclared Peanuts in Cookies

Melanie Wholesale Issues Allergy Alert on Undeclared Peanuts in Cookies

Melanie Wholesale Inc. of Brooklyn, NY is recalling its 17.6 oz (500g) package of “Melanie Liubitelskie Cookies”, because they contain undeclared peanuts. People who have allergies to peanuts run the risk of serious or life-threatening allergic reaction if they consume these products.

FDA - U.S. Food and Drug Administration

15-5-2018

Watch out for ticks with the return of warmer weather!

Watch out for ticks with the return of warmer weather!

The return of warmer weather is particularly conducive to walks in natural surroundings, including woods and forests, as well as activities in the garden. It is therefore a good time to recall the precautions to take in order to avoid tick bites – also unfortunately in season. Especially active in the spring and autumn, ticks remain the most common vectors of pathogens responsible for infectious diseases in Europe. A single bite is enough to transmit the Lyme disease bacterium, the main tick-borne diseas...

France - Agence Nationale du Médicament Vétérinaire

10-1-2019


Orphan designation: autologous CD34+ haematopoietic stem and progenitor cells genetically modified with the lentiviral vector IDUA LV, encoding for the alpha-L-iduronidase cDNA, Treatment of mucopolysaccharidosis type I, 26/10/2018, Positive

Orphan designation: autologous CD34+ haematopoietic stem and progenitor cells genetically modified with the lentiviral vector IDUA LV, encoding for the alpha-L-iduronidase cDNA, Treatment of mucopolysaccharidosis type I, 26/10/2018, Positive

Orphan designation: autologous CD34+ haematopoietic stem and progenitor cells genetically modified with the lentiviral vector IDUA LV, encoding for the alpha-L-iduronidase cDNA, Treatment of mucopolysaccharidosis type I, 26/10/2018, Positive

Europe - EMA - European Medicines Agency

29-10-2018

Synflorix (GlaxoSmithKline Biologicals S.A.)

Synflorix (GlaxoSmithKline Biologicals S.A.)

Synflorix (Active substance: Pneumococcal polysaccharide conjugate vaccine (adsorbed)) - Centralised - Yearly update - Commission Decision (2018)7257 of Mon, 29 Oct 2018

Europe -DG Health and Food Safety